Showing results (1741-1750 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|February 18, 2010
Anticancer activity and mode of action of titanocene CUlrike Olszewski, James Claffey, Megan Hogan, et al.
Investigational New Drugs|May 4, 2017
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosisYuan-Hung Kuo, I-Pei Wu, Jing-Houng Wang, et al.
Investigational New Drugs|September 23, 2016
Propolis extracts from the northern region of Thailand suppress cancer cell growth through induction of apoptosis pathwaysSupakit Khacha-Ananda, Khajornsak Tragoolpua, Panuwan Chantawannakul, et al.
Investigational New Drugs|June 21, 2017
Phase II study of Amrubicin monotherapy in elderly or poor-risk patients with extensive disease of small cell lung cancerSatoshi Igawa, Sakiko Otani, Shinichiro Ryuge, et al.
Investigational New Drugs|October 24, 2009
Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic miceJimmie Colon, Md Riyaz Basha, Rafael Madero-Visbal, et al.
Investigational New Drugs|November 26, 2009
Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618Susanne M Arnold, James Moon, Stephen K Williamson, et al.
Investigational New Drugs|November 26, 2009
Complete remission of ovarian cancer induced intractable malignant ascites with intraperitoneal bevacizumab. Immunological observations and a literature reviewFilippo Bellati, Chiara Napoletano, Ilary Ruscito, et al.
Investigational New Drugs|October 30, 2009
A coumarin derivative (RKS262) inhibits cell-cycle progression, causes pro-apoptotic signaling and cytotoxicity in ovarian cancer cellsRakesh K Singh, Thilo S Lange, Kyu Kwang Kim, et al.
Investigational New Drugs|November 28, 2009
Phase II study of vinorelbine monotherapy in anthracycline and taxane pre-treated metastatic breast cancerHee Yeon Seo, Hyun Joo Lee, Ok Hee Woo, et al.
Investigational New Drugs|December 17, 2009
Hypoxia-targeting by tirapazamine (TPZ) induces preferential growth inhibition of nasopharyngeal carcinoma cells with Chk1/2 activationBo Hong, Vivian W Y Lui, Edwin P Hui, et al.
Pageof 372